AstraZeneca reports sales drop for Evusheld. Why is the variant-busting COVID med underachieving? Altarum: Healthcare spending declined in Q1 for the first time in decades Dexcom to resubmit G7 glucose monitor software for FDA review, pushing back US launch AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor Bristol Myers Squibb partners with Jack and Jill of America to boost diversity in pharma workforce HHS to distribute 786K in monkeypox vaccines but won't declare public health emergency Zimmer Biomet plans AI center to smarten up its hip, knee replacement robots FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should 'move into a new phase' Bausch takes hit in Xifaxan patent feud, potentially paving the way for Norwich's IBS-D generic Molina Healthcare to slash two-thirds of real estate footprint amid permanent shift to remote work Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy Bausch + Lomb kicks off TikTok challenge for Lumify, asking consumers to 'dance with their eyes' Featured Story | By Kevin Dunleavy When AstraZeneca reported its second quarter earnings, sales of Evusheld came in at $445 million—a startling decline from the $469 million it generated in the first quarter. Still, the company is predicting sales of the one-of-its-kind COVID product will increase in the second half. read more |
| |
|---|
|
Top Stories By Paige Minemyer Health spending declined for the first time in more than 60 years during the first quarter, according to a new analysis from Altarum. read more By Conor Hale Diabetes tracker developer Dexcom is pushing back the timeline for a U.S. launch of the latest generation of its continuous glucose monitor, the G7, after the FDA raised questions about the device’s software during a review. read more By Nick Paul Taylor AstraZeneca has axed a Moderna-partnered cardiovascular disease candidate from its phase 2 pipeline. Months after reporting positive trends on exploratory efficacy endpoints, the Big Pharma has pushed the mRNA candidate out the door while also dropping its Wee1 inhibitor after many years of development. read more By Natalie Missakian Last year, Bristol Myers Squibb partnered with historically Black colleges and universities to help groom Black college students for future jobs in the pharma industry. Now it’s expanding that effort to catch potential hires even earlier – by engaging younger students and their parents. read more By Robert King HHS announced the distribution of another 786,000 doses of monkeypox vaccine on Thursday to states and localities, but demurred on declaring a public health emergency. read more By Conor Hale Through a three-year project with the Hospital for Special Surgery, Zimmer Biomet hopes to assemble decision support tools for joint replacements powered by its Rosa robots. read more By Max Bayer Robert Califf threw his support behind the FDA's longstanding cancer czar, backing a proposal by Richard Pazdur for the agency to be more judicious in accepting single-arm trial data to nab accelerated approval. The prospect of limiting the trials has irked some in the biopharma industry. read more By Fraiser Kansteiner Bausch and its gastroenterology unit Salix Pharmaceuticals said Thursday that a Delaware federal court issued an oral order scrapping some patents on Xifaxan 550mg tablets. Bausch says it will contest the decision at the U.S. Court of Appeals for the Federal Circuit. read more By Paige Minemyer Molina Healthcare will significantly reduce its real estate footprint as it moves to remote work permanently, executives said on the company's earnings call Thursday morning. read more By Annalee Armstrong Sarepta Therapeutics’ shares saw a nice boost early Friday morning as the biotech declared its intent to seek an early accelerated approval for the Roche-partnered Duchenne muscular dystrophy gene transfer therapy SRP-9001. read more By Ben Adams Bausch + Lomb is tapping into the social media craze for TikTok in a unique marketing campaign for its eye drop Lumify. The campaign asks you not to dance with your feet but with your eyes and offers up a chance to win a makeover with Vincent Oquendo. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 